152 related articles for article (PubMed ID: 8315429)
1. Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms: a phase I/II study.
Thompson DS; Hainsworth JD; Hande KR; Holzmer MC; Greco FA
J Clin Oncol; 1993 Jul; 11(7):1322-8. PubMed ID: 8315429
[TBL] [Abstract][Full Text] [Related]
2. Prolonged administration of low dose infusional etoposide in patients with advanced malignancies. A phase I/II study.
Thompson DS; Hainsworth JD; Hande KR; Holzmer M; Greco FA
Cancer; 1994 Jun; 73(11):2824-31. PubMed ID: 8194024
[TBL] [Abstract][Full Text] [Related]
3. Prolonged administration of oral etoposide in non-small-cell lung cancer: a phase II trial.
Waits TM; Johnson DH; Hainsworth JD; Hande KR; Thomas M; Greco FA
J Clin Oncol; 1992 Feb; 10(2):292-6. PubMed ID: 1310104
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen.
Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Raphael B; Vinci RZ
J Clin Oncol; 1994 Mar; 12(3):553-9. PubMed ID: 8120553
[TBL] [Abstract][Full Text] [Related]
5. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
6. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial.
Johnson DH; Greco FA; Strupp J; Hande KR; Hainsworth JD
J Clin Oncol; 1990 Oct; 8(10):1613-7. PubMed ID: 2170589
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacologic study of 7- and 21-day continuous etoposide infusion in patients with advanced cancer.
Robert F; Chen S; Miller AA; Lee BC; Molthrop DC; Wheeler RH
Cancer Chemother Pharmacol; 1996; 38(5):459-65. PubMed ID: 8765440
[TBL] [Abstract][Full Text] [Related]
8. Phase I clinical and pharmacokinetic study of a 14-day infusion of etoposide in patients with lung cancer.
Minami H; Shimokata K; Saka H; Saito H; Ando Y; Senda K; Nomura F; Sakai S
J Clin Oncol; 1993 Aug; 11(8):1602-8. PubMed ID: 8336196
[TBL] [Abstract][Full Text] [Related]
9. Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors.
Budman DR; Igwemezie LN; Kaul S; Behr J; Lichtman S; Schulman P; Vinciguerra V; Allen SL; Kolitz J; Hock K
J Clin Oncol; 1994 Sep; 12(9):1902-9. PubMed ID: 8083713
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of high dose etoposide phosphatase with filgrastim (G-CSF) in the treatment of advanced refractory malignancies.
Hainsworth JD; Utley SM; Greco FA
Invest New Drugs; 1997; 15(4):325-9. PubMed ID: 9547675
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of high-dose melphalan, high-dose etoposide and autologous bone marrow re-infusion in solid tumors: an Eastern Cooperative Oncology Group (ECOG) study.
Lazarus HM; Gray R; Ciobanu N; Winter J; Weiner RS
Bone Marrow Transplant; 1994 Sep; 14(3):443-8. PubMed ID: 7994270
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of high-dose etoposide phosphate in man.
Fields SZ; Budman DR; Young RR; Kreis W; Ingram R; Schulman P; Cherny RC; Wright J; Behr J; Snow C; Schacter LP
Bone Marrow Transplant; 1996 Nov; 18(5):851-6. PubMed ID: 8932836
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities.
Hainsworth JD; Gray JR; Stroup SL; Kalman LA; Patten JE; Hopkins LG; Thomas M; Greco FA
J Clin Oncol; 1997 Dec; 15(12):3464-70. PubMed ID: 9396399
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacokinetic study of etoposide phosphate by protracted venous infusion in patients with advanced cancer.
Soni N; Meropol NJ; Pendyala L; Noel D; Schacter LP; Gunton KE; Creaven PJ
J Clin Oncol; 1997 Feb; 15(2):766-72. PubMed ID: 9053503
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of etoposide phosphate administered as a daily 30-minute infusion for 5 days.
Thompson DS; Greco A; Miller AA; Srinivas NR; Igwenezue KB; Hainsworth JD; Schacter LP; Kaul S; Barbhaiya RH; Garrow C
Clin Pharmacol Ther; 1995 May; 57(5):499-507. PubMed ID: 7768072
[TBL] [Abstract][Full Text] [Related]
16. Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non-Hodgkin's lymphoma: evidence for a schedule-dependent effect favoring infusional administration of chemotherapy.
Sparano JA; Wiernik PH; Leaf A; Dutcher JP
J Clin Oncol; 1993 Jun; 11(6):1071-9. PubMed ID: 8501493
[TBL] [Abstract][Full Text] [Related]
17. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
Krigel RL; Palackdharry CS; Padavic K; Haas N; Kilpatrick D; Langer C; Comis R
J Clin Oncol; 1994 Jun; 12(6):1251-8. PubMed ID: 8201386
[TBL] [Abstract][Full Text] [Related]
18. Fractionated doses of oral etoposide in the treatment of patients with aids-related kaposi sarcoma: a clinical and pharmacologic study to improve therapeutic index.
Sprinz E; Caldas AP; Mans DR; Cancela A; DiLeone L; Dalla Costa T; Schwartsmann G
Am J Clin Oncol; 2001 Apr; 24(2):177-84. PubMed ID: 11319295
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers.
Schaefer PL; Marks RS; Mahoney MR; Sloan JA; Bauman MD; Tazelaar HD; Kugler JW; Mailliard JA; Ebbert LP; Wiesenfeld M
Am J Clin Oncol; 2003 Jun; 26(3):236-40. PubMed ID: 12796591
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
Masuda N; Fukuoka M; Kudoh S; Matsui K; Kusunoki Y; Takada M; Nakagawa K; Hirashima T; Tsukada H; Yana T
J Clin Oncol; 1994 Sep; 12(9):1833-41. PubMed ID: 7521905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
